Clinical Trial Details
— Status: Terminated
Administrative data
| NCT number |
NCT02935556 |
| Other study ID # |
PRO00104636 |
| Secondary ID |
|
| Status |
Terminated |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
February 1, 2017 |
| Est. completion date |
March 9, 2022 |
Study information
| Verified date |
March 2024 |
| Source |
Duke University |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
This study will recruit women with post partum pre-eclampsia and match them to controls
without postpartum pre-eclampsia to identify an epigenetic signature that is specific to
women with post partum pre-eclampsia to help characterize the underlying pathophysiology of
post partum pre-eclampsia.
Description:
Preeclampsia (PEC) is a heterogeneous disease that complicates 5-8% of pregnancies.
Approximately 10% of PEC patients will present with post-partum PEC without having developed
the syndrome during the pregnancy (PP-PEC). Management of post-partum preeclampsia (PP-PEC)
is challenging because many women do not seek care until neurologic symptoms result from
severe-range elevated blood pressure. The pathogenesis and clinical characteristics of PP-PEC
are understudied and poorly understood. Identifying clinical risk factors and biomarkers of
PP-PEC would help to identify women at risk.
